SCHEMBL25876241

SCHEMBL25876241

COC(=O)C1(OC)CC=C(c2nc(C)c3cnn(CCF)c3n2)CC1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25876281 0.93 PDE1A (0.34) MEN1KMT2ASMN1; SMN2
SCHEMBL25875947 0.91 MEN1 (0.37) MEN1KMT2ASMN1; SMN2
SCHEMBL25876305 0.89 PIK3CA (0.39)
SCHEMBL25875975 0.89
SCHEMBL25875751 0.88 TP53 (0.32) KMT2A
SCHEMBL25876085 0.87 MERTK (0.33)
SCHEMBL25875899 0.84 KLKB1 (0.33)
SCHEMBL25876137 0.83 PIK3CA (0.35)
SCHEMBL25876054 0.82 PDE9A (0.31)
SCHEMBL25876258 0.81 PIK3CA (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234954-A1 COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF TYK MEDICINES, INC. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234954-A1 COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF RET, ROR1, FGFR3 MEN1 614/4885KMT2A 585/4885SMN1; SMN2 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.